Chronic Pain, Insomnia, Exercise, Sleep, Sleep Disorder, Opioid Use
Conditions
Keywords
Accelerometry, Mental fatigue, Self-Efficacy
Brief summary
Pain is one of the most common causes of healthcare contact and long-term sick leave, with negative consequences on physical and mental health. Poor sleep is common in chronic pain patients. Epidemiological studies indicate that 5-7% of patients with chronic pain are treated regularly with strong opioids. Negative side effects of pain modulating drugs on sleep quality have been reported, which may have negative influence on overall disease management in chronic pain patients. However, to date there are conflicting results regarding the effects of opioids on sleep, since the pain relieving effect of opioids seem to affect sleep positively. There is data suggesting that physical activity has positive effects on both pain perception and sleep quality (and duration). The aim of the study is to explore insomnia and characteristics of sleep in patients with chronic pain and the relationship with physical activity level and opioid use.
Detailed description
One hundred participants with planned follow-up (decision according to clinical routine) at the Pain Centre will be consecutively recruited. After signed informed consent, the participants will wear two accelerometers during one week, one for recording sleep and one for recording physical activity. The participants will be asked to fill out a sleep and pain diary during the same week. Furthermore, the participants will fill out questionnaires regarding sleep, life style, mental fatigue and self-efficacy. All study participant are included in the Swedish Quality Registry for Pain Rehabilitation (SQRP). Data from the SQRP will be used regarding patient health characteristics, pain and pain associated symptoms, health related quality of life, sleep and self-reported physical activity level. Data regarding co-morbidity, drug use, pharmacological treatment and other interventions at the Pain Center will be collected from the patient charts. In addition, the participants blood pressure and neck circumference will be measured. Blood samples will be analysed for biomarkers associated with pain and sleep disturbance.
Interventions
DEVICEAccelerometry
Recording of sleep and physical activity by accelerometry during one week.
Sponsors
Vastra Gotaland Region
Göteborg University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic pain (i.e. pain \> 3 months) * Planned follow up at the Pain Centre * Age ≥18 years * Consents to participation in the study
Exclusion criteria
* Inadequate knowledge of the Swedish language * Alcohol or substance abuse * Severe untreated psychiatric disorders including psychiatric disease and/or psychological conditions which are the primary determinant to the patient's pain condition * Malignant disease with short expected survival
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain intensity | Daily assessment during one week | Pain intensity according to Numeric Rating Scale (NRS), score from 0 to 10, where 0 is described as no pain and 10 as worst pain imaginable |
| Opioid consumption | Opioid consumption at study enrollment | Opioid consumption in morphine equivalent doses |
| Sleep | Daily assessment during one week | Sleep duration in minutes assessed by accelerometry |
| Physical activity | Daily assessment during one week | Minutes of physical activity per week at moderate and vigorous intensity physical activity (MVPA), minutes of sedentary behaviour (SED) assessed by accelerometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-assessed physical activity | Self-assessed physical activity at study enrollment | Minutes of physical activity per week (physical exercise and daily exercise) and minutes of sedentary behaviour per week. |
| Mental fatigue scale | Mental fatigue at study enrollment | The mental fatigue scale (MFS) is a multidimensional questionnaire containing 15 questions. A total score between 0-42 is calculated. A score \>10 indicates a problem with mental fatigue. |
| Sleep dairy | Daily assessment during one week | Self-assessed sleep latency, total sleep time, wake time after sleep onset and sleep quality. |
| Self-efficacy for exercise scale | Self-efficacy for exercise at study enrollment | The Self-efficacy for exercise scale measures a patient's self-efficacy when it comes to physical exercise. The questionnaire consists of 9 questions that can be answered on a 1-10 scale. A total score between 9 and 90 is calculated, were a higher number represent a better outcome. |
| Insomnia Severity | Insomnia severity at enrollment | Total Score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia. |
| Sleep quality | Sleep quality at study enrollment | Assessed with the Pittsburgh Sleep Quality Index (PSQI). The PSQI consists of 19 self-rated questions which assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep related problems. The 19 items are grouped into seven component scores, each weighted equally on a 0-3 scale. The seven component score are then summed to yield a global PSQI score which has a range of 0-21; higher scores indicate worse sleep quality. |
| Daytime sleepiness | Daytime sleepiness at study enrollment | Epworth Sleepiness Scale (ESS), which quantifies daytime sleepiness. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher daytime sleepiness. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Neurofilament light | Neurofilament light at study enrollment | Neurofilament light in blood sample |
| 25-hydroxyvitamin D | 25-hydroxyvitamin D at study enrollment | Levels of Serum 25-hydroxyvitamin D (25\[OH\]D) |
Countries
Sweden
Contacts
Primary ContactPaulin Andréll, MD, PhD
Backup ContactMartin Olsson, MD
Outcome results
None listed